Latest Health News

Percheron Therapeutics reduced its FY2026 loss to $4.79 million as it prepares to launch a pivotal phase II trial for its immuno-oncology drug HMBD-002, while managing a CEO transition and tightening cash reserves.

Artrya Limited marked its first full year of US commercial operations with a $25.18 million loss, driven by regulatory clearances, customer contracts, and an $80 million capital raise.

ImpediMed has secured FDA 510(k) clearance for its SOZO Digital Health Platform to assess sarcopenia risk, marking it as the only FDA-cleared bioimpedance spectroscopy solution for this clinical application. This clearance enables clinicians to non-invasively monitor muscle loss in cancer and chronic disease patients, potentially improving treatment outcomes.

Healius Limited posted a modest revenue increase and underlying loss improvement for FY26, overshadowed by a substantial non-cash goodwill impairment and ongoing sector pressures.

Service Stream Limited (ASX: SSM) posted a modest 1.1% revenue rise to $2.35 billion for FY26, driven by Utilities and Asset & Facility Management growth, including a new Defence contract. EBITDA from operations surged 11.8% to $163.4 million, while statutory NPAT dipped 3.8% due to $21.2 million in ERP modernization costs. The company declared a final dividend increase to 3.5 cents per share.

Viva Leisure posted a 12.2% revenue increase to $237.1 million and a 144.5% jump in net profit after tax for FY2026, declaring its first fully franked dividend and launching Meridium Global as a standalone payments and technology business.

AVITA Medical's PermeaDerm biosynthetic wound matrix delivers clinical outcomes on par with allograft while slashing treatment costs by 70%, according to a new multicenter study.

EBOS Group posted a solid FY26, growing revenue nearly 10% to $13.5 billion and underlying EBITDA 5% to $614 million, while completing a major distribution centre renewal program. The company maintains its final dividend and sets a confident growth outlook for FY27.

Pro Medicus delivered a robust FY26 with 28% underlying revenue growth, a surge in new contract wins worth $407 million, and a 25% increase in fully franked dividends, underpinned by strong AI product development and rapid implementations.

Macmahon Holdings delivered a tenth consecutive year of growth with revenue up 7.9% to $2.6 billion and net profit after tax soaring 36.8% to $101.1 million, underpinned by strong contract wins and operational discipline.

Synertec Corporation Limited (ASX:SOP) reported a 19% revenue increase in FY26 alongside its first net operating cash inflow since FY19. The company raised approximately A$6 million through an institutional placement to support working capital and growth initiatives while reaffirming FY27 revenue guidance.

Doctor Care Anywhere delivered a 27% rise in EBITDA and doubled free cash flow in H1 2026, driven by operational efficiencies and a strategic entry into the UK weight management market via acquisition.